Novo Nordisk ADR (NYSE: NVO) currently trades at $89 per share, nearly 40% below its peak level of over $145 seen in June of ...

Pharmaceutical stalwart Novo Nordisk (NVO) can’t seem to get anything good going these days. As TipRanks’ Vince Condarcuri ...

Novo Nordisk A/S (NYSE:NVO) ranks 11th on our list of the best ... If you are looking for an AI stock that is more promising ...

As of 11:05 a.m. ET, Novo Nordisk stock is down a disheartening 20.8%, while both Lilly and Viking stocks are up 4.4% apiece.

Amidst a race with its competitors to produce the next smash-hit weight loss drug, Novo Nordisk 's ( NVO -1.51%) stock ...

Novo Nordisk stock was down nearly 25% at one point on Friday. Its anti-obesity rival, Eli Lilly & Co, in comparison, jumped ...

The general mood among these heavyweight investors is divided, with 50% leaning bullish and 31% bearish. Among these notable ...

The Ozempic maker's stock tanked after its highly anticipated CagriSema drug trial showed an average of 22.7% weight loss, ...

Analysts have set 12-month price targets for Novo Nordisk, revealing an average target of $145.25, a high estimate of $160.00 ...

CagriSema, a drug that Novo had hoped would become the next generation weight-loss aid, failed to meet expectations in ...

Shares in Ozempic maker Novo Nordisk crashed, after an experimental anti-obesity shot fell short of expectations. The shares ...

Financial writer sees Novo Nordisk's stock drop as a buying opportunity after disappointing trial results, citing strong ...